Wikipedia:BIND-014

BIND-014 is a targeted polymeric nanoparticle, and is an investigational therapeutic drug in phase 2 clinical trials for various cancers, e.g. metastatic prostate cancer

BIND-014 is an Accurin nanomedicine produced by Bind Therapeutics Inc. BIND-014 targets prostate-specific membrane antigen (PSMA), which is expressed on prostate cancer cells and the blood vessels of many types of solid tumors, and contains docetaxel as the cytotoxic agent.

Positive results in non-small cell lung cancer were presented in late 2014.

Bind Therapeutics Inc. declared bankruptcy in 2017, halting development of the agent.